Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at firstname.lastname@example.org if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
The Learning Portal will be under maintenance Monday, 6 December between 6 AM and 5 PM EST. Portal functionality will be unavailable during this window.
We apologize for any inconvenience caused during this time.
Posted 14 November 2014 | By Alexander Gaffney, RAC,
US legislators in the House of Representatives have passed a Senate bill which would overhaul the manner in which the US Food and Drug Administration (FDA) approves sunscreen ingredients and other products through a rarely used regulatory pathway known as the Time-and-Extent process (TEA), all but assuring the bill will be passed into law.
The bill, known as the Sunscreen Innovation Act (SIA), follows extensive complaints by several companies that their sunscreen products—long marketed in other countries—have been unnecessarily held up by FDA officials.
For a thorough explanation of this, please see Focus' explainer on the regulation of sunscreen ingredients.
Those products have been seeking to access the market as over-the-counter (OTC) drugs through FDA's TEA process—a rarely used procedure meant to allow products to be approved for use in the US based on their use in other countries.
Sponsors of TEAs must undergo a five-part process, any part of which can experience lengthy delays:
While the TEA process is meant to be speedy in concept, in practice it has proven to be anything but. Since FDA lacks the data it often relies upon for approvals, it has delayed some ingredients for nearly a decade, seeking more and better data in support of TEA applications. In addition, because products are approved in different ways across regions—sunscreen ingredients are actually cosmetics in the EU—it can often be difficult to rely upon data from outside the US.
An early iteration of the Sunscreen Innovation Act introduced in the House of Representatives was intended to reform the TEA process, but only as it specifically applied to sunscreen ingredients.
The House bill called for FDA to review all sunscreen ingredients that would be eligible under the TEA process through an expedited process. That process would see applications reviewed in a timeframe measured in months instead of years. Even accounting for delays (such as FDA seeking additional data), most submissions would likely be able to receive approval within two years of submission.
The bill called for existing applications to be reviewed within 8 months, and new submissions to be reviewed within 11 months, FDA Law Blog reported.
The Senate, however, introduced a more expansive version of the bill in September containing mostly identical language to the House bill but also focusing on "non-sunscreen" TEAs.
The bill specifically calls for FDA to issue regulations within 18 months of the bill's passage to provide for the "timely and efficient" review of TEA applications "for drugs other than nonprescription sunscreen active ingredients or combinations of nonprescription sunscreen active ingredients." The regulations are to set "reasonable timelines" for the review and approval of medications and also provide "measurable metrics" for ensuring those goals are met.
The guidelines may, however, "vary based on the content, complexity and format of the application submitted." That's important for FDA regulators, who have highlighted major data deficiencies in some TEA applications. Some sunscreen ingredients, for example, are actually regulated as cosmetic products in other countries, meaning FDA sometimes has little or insufficient data to support findings of safety or efficacy.
Now the bill, approved by the Senate since 17 September 2014, has passed the House as well, clearing its way for approval from President Barack Obama. The bill was passed in the house "without objection," according to congressional records.
The bill is expected to be signed into law after receiving overwhelming support in both the House and Senate, giving it the ability to overcome a veto of the bill by the president in the unlikely event that such a veto occurred.
Sunscreen Innovation Act (S.2141)
Tags: Congress, House, Senate, Sunscreen Innovation Act, Sunscreen, Legislation, Bill, TEA, Time and Extent, Time-and-Extent, GRASE
Regulatory Focus newsletters
All the biggest regulatory news and happenings.